Roche, Hitachi High-Tech to Continue Partnership

Roche and Hitachi High-Tech are continuing their 46-year partnership for another decade. the companies will be use their combined expertise through 2034 to track and develop diagnostics solutions as well as engineering and manufacturing technologies. 

The pair has been collaborating on new diagnostics technology since 1978 and has resulted in a global reach of more than 84,000 installed diagnostic units. The companies have developed numerous in-vitro diagnostics innovations, including the ‘serum work area” concept that integrates clinical chemistry and immunochemistry into one system.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving people’s lives. Roche partners with many stakeholders and combines its strengths in diagnostics and pharmaceuticals with data insights from clinical practice. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Hitachi High-Tech, headquartered in Tokyo, is engaged in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. The company also provides high value-added solutions in industrial fields such as mobility, connected, environment and energy, etc. The company’s consolidated revenues for FY2023 were approximately 670.4 billion yen.